Granules India Limited Expands Reach with Senn Chemicals AG Acquisition
Granules India Limited has finalized the acquisition of Senn Chemicals AG, a Swiss-based contract development and manufacturing organisation (CDMO) known for its specialization in peptides, for Rs 192 crore. The completion of this acquisition, which is contingent upon specific conditions, is anticipated in the first half of 2025, according to a company statement.
Expertise in Peptide Synthesis
Senn Chemicals AG contributes valuable expertise in both liquid-phase and solid-phase peptide synthesis, along with its established CDMO operations and customer relationships across various sectors. This includes partnerships with innovators and brand owners in the pharmaceutical, cosmetics, amino acid derivatives, and theragnostic markets.
Strategic Expansion into Peptide Therapeutics
Dr Krishna Prasad Chigurupati, the Chairman and Managing Director of Granules India, mentioned that entering the rapidly growing peptide therapeutics segment and acquiring CDMO capabilities aligns with the company’s dedication to innovation and cost-effectiveness. The combination of Senn’s advanced peptide synthesis knowledge with Granules’ large-scale and efficient manufacturing capabilities is set to facilitate the delivery of premium peptide-based solutions worldwide.
Growth Opportunities in Peptide-based Therapeutics
This acquisition allows Granules to enhance its capabilities in the fast-growing field of peptide-based therapeutics. The company plans to penetrate the expanding markets of peptide-based anti-diabetic and anti-obesity treatments. Senn, renowned for developing and manufacturing peptides and related applications for global clients, will also provide Granules access to a skilled R&D talent pool and clients in regulated markets, aiding in the expansion of Granules’ global presence.
Strengthening Strategic Partnerships
Dr Rico Wiedenbruch, Chairman of Senn Chemicals AG, remarked on the strategic fit and vast potential of this partnership, emphasizing that Granules’ scale, operational efficiency, and global reach in the pharmaceutical industry will significantly accelerate growth. This collaboration aims to enhance capabilities in the burgeoning field of peptide therapeutics while advancing innovations in peptide development and manufacturing.
[ad_1]